Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Annals of HematologyOpen Access

Gene expression analysis of patients with chronic myeloid leukemia who discontinued tyrosine kinase inhibitor

View Full Paper
Ask AI
Bookmark
Share

Authors

HPHyunkyung ParkHKHyeong Joon KimSSSang‐Kyun Sohn

Discussion

Loading...

Member takes

Overview

Prospective analysis explores immune-related gene differences predicting molecular relapse after TKI cessation in chronic myeloid leukemia patients.

Key Points

  • About 47.6% of patients experienced molecular relapse during a median follow-up of 16.9 months.
  • The 6- and 12-month molecular relapse-free survival rates were approximately 52.5% and 50%, respectively.
  • Significant gene expression differences linked to T cell activity were observed between relapsed and non-relapsed patients.
  • Longer duration of deep molecular response is associated with a better survival rate post TKI discontinuation.

Cite This Study

Park et al. (2025) studied this question.

synapsesocial.com/papers/68c23e4fb210217d647920eehttps://doi.org/10.1007/s00277-025-06514-8
View Full Paper
Ask AI
Bookmark
Share